Key result
Two male patients with hypokalemic periodic paralysis exhibited similar clinical manifestations despite harboring mutations in two different genes, CACNA1S (p.Arg528His) and SCN4A (p.Arg672His).
Case Report (n=2)
Molecular genetic diagnosis is important in hypokalemic periodic paralysis for genetic counseling and selecting appropriate preventive treatment, as different gene mutations may respond differently to acetazolamide despite similar clinical presentations.
Primary hypokalemic periodic paralysis (HOKPP) is an autosomal dominant disorder manifesting as recurrent periodic flaccid paralysis and concomitant hypokalemia. HOKPP is divided into type 1 and type 2 based on the causative gene. Although 2 different ion channels have been identified as the molecular genetic cause of HOKPP, the clinical manifestations between the 2 groups are similar. We report the cases of 2 patients with HOKPP who both presented with typical clinical manifestations, but with mutations in 2 different genes (CACNA1Sp.Arg528His and SCN4A p.Arg672His). Despite the similar clinical manifestations, there were differences in the response to acetazolamide treatment between certain genotypes of SCN4A mutations and CACNA1S mutations. We identified p.Arg672His in the SCN4A gene of patient 2 immediately after the first attack through a molecular genetic testing strategy. Molecular genetic diagnosis is important for genetic counseling and selecting preventive treatment.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2011) conducted a case report in Hypokalemic periodic paralysis (n=2). CACNA1S and SCN4A mutations was evaluated. Two male patients with hypokalemic periodic paralysis exhibited similar clinical manifestations despite harboring mutations in two different genes, CACNA1S (p.Arg528His) and SCN4A (p.Arg672His).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: